This article is for informational purposes only. It is not medical advice. GLP-1 medications require a prescription and clinical evaluation. Consult a licensed healthcare professional before starting any medication.
If you have been researching weight loss options online recently, you have almost certainly encountered the term GLP-1. Maybe it came up in a news article about MEDVi. Maybe a friend mentioned semaglutide or tirzepatide. Maybe you saw an ad promising dramatic results from a weekly injection and wanted to know what was actually going on before you committed your money or your health to anything.
This is the explainer you need before you evaluate any specific platform, pricing page, or promotional claim. It covers what GLP-1 medications are, how they work in your body, what the clinical evidence actually shows, and what you should understand about the difference between branded and compounded versions before making any decisions.
What GLP-1 Actually Is
GLP-1 stands for glucagon-like peptide-1. It is a hormone your body already produces. After you eat, specialized cells in your intestine release GLP-1 into your bloodstream. That hormone does several things at once. It signals your pancreas to release insulin, helping regulate blood sugar. It slows the rate at which food leaves your stomach, which keeps you feeling full longer. And it communicates with appetite centers in your brain, reducing the urge to eat.
Your body produces GLP-1 naturally after every meal. The problem, for people struggling with obesity or metabolic conditions, is that the natural hormone breaks down within minutes. It does its job briefly, then disappears.
GLP-1 receptor agonist medications — semaglutide and tirzepatide are the two you hear about most — are engineered versions of that hormone designed to last much longer in the body. A single weekly injection of semaglutide maintains GLP-1 activity for roughly seven days instead of two minutes. That sustained activity produces significantly stronger effects on appetite, blood sugar, and weight than the body's natural GLP-1 pulse can achieve on its own.
What the Clinical Evidence Shows
GLP-1 medications did not become popular because of marketing. They became popular because the clinical trial results were unlike anything the weight loss field had produced in decades.
The STEP trials for semaglutide showed average weight loss of approximately 15 percent of body weight over 68 weeks. The SURMOUNT trials for tirzepatide — which activates both GLP-1 and GIP receptors — showed even larger effects, with some dose groups averaging over 20 percent body weight reduction. For a 250-pound person, that translates to 37 to 50 pounds of weight loss with medication plus lifestyle modification.
Beyond weight, these medications demonstrated improvements in cardiovascular risk factors, blood sugar control, blood pressure, and inflammatory markers. The SELECT trial showed that semaglutide reduced major cardiovascular events by 20 percent in adults with obesity and established cardiovascular disease — leading to the first FDA approval of a weight loss medication based on cardiovascular benefit.
These are real clinical findings from large, well-designed trials published in peer-reviewed journals. They do not mean that every person will experience these results. Individual outcomes depend on dosage, adherence, diet, exercise, baseline health, and genetics. But the evidence base is stronger than for any prior class of weight loss medication.
Branded vs. Compounded: The Distinction That Matters Most
Here is where most consumers get confused, and where getting confused can cost you money or put your health at unnecessary risk.
Branded GLP-1 medications — Ozempic, Wegovy, Mounjaro, and Zepbound — are manufactured by Novo Nordisk and Eli Lilly. They went through the full FDA approval process including large-scale clinical trials. They are manufactured under strict federal quality standards. They typically cost over $1,000 per month without insurance.
Compounded GLP-1 medications use the same active ingredients but are prepared by compounding pharmacies rather than the original manufacturers. They have not been individually evaluated by the FDA as finished products. They typically cost $150 to $400 per month — a fraction of branded pricing.
The active molecule is the same. The regulatory oversight of the finished product is not. That distinction does not automatically make compounded versions dangerous, but it does mean you are relying on the compounding pharmacy's quality controls rather than the FDA's pre-market review. Asking which pharmacy compounds your medication, whether it is a 503A or 503B facility, and whether they can provide a Certificate of Analysis are reasonable steps any informed consumer should take.
If you arrived at this article after reading our MEDVi fact-check, you already know that MEDVi primarily offers compounded GLP-1 medications. That fact-check covers the company's specific regulatory situation, pricing, and consumer review data in detail.
What GLP-1 Side Effects Look Like in Practice
The most commonly reported side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation. These effects are usually most pronounced during the first few weeks and during dose escalation periods, then diminish as the body adjusts.
More serious but less common risks include pancreatitis, gallbladder problems, and potential thyroid concerns. GLP-1 medications carry a boxed warning regarding thyroid C-cell tumors based on animal studies, though this risk has not been confirmed in humans. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take these medications.
The dose escalation protocol — starting at a low dose and increasing gradually over weeks — exists specifically to manage side effects. Rushing to a higher dose increases the likelihood of nausea and other GI problems. Any reputable telehealth platform or prescribing clinician should follow a structured titration schedule.
The Regulatory Landscape You Need to Understand
The compounded GLP-1 market exploded during 2023 and 2024 when branded medications were in shortage. Federal regulations allow expanded compounding access during documented shortages. But the FDA declared the semaglutide injection shortage resolved in February 2025, and approved an oral version of Wegovy in December 2025. Both developments narrowed the legal basis for mass-marketed compounding.
In March 2026, the FDA issued warning letters to more than 30 telehealth companies for misleading marketing of compounded GLP-1 products. This was not a crackdown on compounding itself — patient-specific compounding remains legal. It was a crackdown on marketing practices that blurred the line between compounded and FDA-approved products.
What this means for you as a consumer: compounded GLP-1 medications are still available, but the landscape is shifting. Verify that any platform you are considering has updated its disclosures to reflect the current regulatory environment. The platforms that survive this enforcement period will be the ones that communicate honestly about what compounded medications are and are not.
What to Do With This Information
If you are considering GLP-1 medication through any provider — telehealth or in-person, branded or compounded — talk with your own doctor first. A healthcare provider who knows your medical history can evaluate whether GLP-1 therapy is appropriate for you, which formulation makes sense, and what monitoring you need during treatment.
If you are evaluating a specific telehealth platform, the facts matter more than the headlines. Our MEDVi fact-check applies the same evidence-based approach to one of the most visible platforms in this space. Read it with the understanding you now have about how the medication works, what compounding means, and what the regulatory environment looks like.
This article is for informational purposes only. It is not medical or legal advice. GLP-1 medications require a prescription and clinical evaluation. Compounded medications are not FDA-approved finished products. Consult licensed professionals for medical guidance.
MedicalFoundationOfNC.org Editorial Team | Published April 2026